BioVaxys LLC logo

BioVaxys LLC

The next generation in patient-specific immunotherapeutic cancer vaccines BioVaxys is a biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma, ovarian cancer, and other solid tumor types.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://biovaxys.com
Founded2018
Disease Focus
Development Stage
STOCK CODENon Listed
Address
152 West 57th St, 24th Floor, NY 10019
New York
United States
Email
Contact Number
+1 610 977 2440

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/biovaxys-llc” connections=”true” suffix=””]

BioVaxys vaccines are created by extracting a patients own (e.g. Çautologous) cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. BioVaxys lead clinical program is to develop the autologous bihaptenized vaccine together with an anti-CTLA4 or anti- PDA checkpoint antibodies for melanoma and ovarian cancer.

In July 2018, BioVaxys and Thomas Jefferson University, a Philadelphia-based professional university; entered into an exclusive worldwide license agreement for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor types.